Theravance Biopharma (TBPH) Capital Expenditures Growth (1y) (2014 - 2025)
Theravance Biopharma (TBPH) Capital Expenditures Growth (1y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -27.93% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -95.79% |
| Dec 31, 2024 | -71.94% |
| Sep 30, 2024 | -28.57% |
| Jun 30, 2024 | -95.77% |
| Mar 31, 2024 | -90.30% |
| Dec 31, 2023 | 154.51% |
| Sep 30, 2023 | 136.84% |
| Jun 30, 2023 | 653.98% |
| Mar 31, 2023 | 275.20% |
| Dec 31, 2022 | -40.09% |
| Sep 30, 2022 | -105.49% |
| Jun 30, 2022 | -27.56% |
| Mar 31, 2022 | -85.85% |
| Dec 31, 2021 | -64.31% |
| Sep 30, 2021 | -49.32% |
| Jun 30, 2021 | -93.41% |
| Mar 31, 2021 | 85.22% |
| Dec 31, 2020 | -4.53% |
| Sep 30, 2020 | 2,562.34% |
| Jun 30, 2020 | 311.11% |